PTRH2 and breast carcinoma: Lastly our breakpoint analysis uncovered recurrent deletions and rearrangements of the CLTC-PTRH2-VMP1 locus, evident in diverse tumor types, including glioblastoma, neuroblastoma, lung cancer, breast cancer, bladder cancer, thyroid cancer, melanoma, and leukemias.